✦ LIBER ✦

VM-26 in colorectal carcinoma: A Southwest Oncology Group study

✍ Scribed by Noboru Oishi; Thomas R. Fleming; Leslie Laufman; James S. Ungerleider; Ronald B. Natale; Albert B. Einstein; Daniel D. Hoff; John S. Macdonald

Publisher: Springer US
Year: 1990
Tongue: English
Weight: 166 KB
Volume: 8
Category: Article
ISSN: 0167-6997
DOI: 10.1007/bf00216931

No coin nor oath required. For personal study only.

✦ Synopsis

In this multi-institutional phase II study, VM-26 or Teniposide was administered to forty-two patients with advanced colorectal cancer. Patients were initially treated at 60 mg/M2 daily for 5 days with dose adjustments depending on toxicity. One complete response and one partial response were observed lasting six and four months respectively. Leukopenia was severe in 40% of patients. No drug related deaths were seen. In this Southwest Oncology Group (SWOG) study, VM-26 appeared to have minimal benefit in advanced colorectal cancer.

📜 SIMILAR VOLUMES

Southwest oncology group strategies in p

Southwest oncology group strategies in prostatic carcinoma

✍ E. David Crawford; Maha Hussain; Edward P. Deantoni; Ian M. Thompson; Mario A. E 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 543 KB

The Southwest Oncology Group Genitourinary Committee evolved in 1978 from a combined gynecologic-urologic cancer committee. A significant catalyst in this development was the growing interest in prostatic carcinoma, with an initial focus on hormone refractory disease. Clinical studies have expanded

Teniposide (VM-26) as a single drug trea

Teniposide (VM-26) as a single drug treatment for patients with extensive small cell lung carcinoma : A Phase II study of the Southwest Oncology Group

✍ Petre N. Grozea; John J. Crowley; Vikki A. Canfield; Laura Kingsbury; S. William 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 74 KB 👁 3 views

## Background: Teniposide (vm-26) was reported to have activity in small cell lung carcinoma (sclc). the authors performed a phase ii study of teniposide as a treatment for patients with previously untreated extensive sclc. ## Methods: The study was open to patients with a histologic or cytologic

Teniposide (VM-26) as a single drug trea

Teniposide (VM-26) as a single drug treatment for patients with extensive small cell lung carcinoma: A phase II study of the southwest oncology group

✍ Jacob J. Lokich 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 83 KB 👁 3 views

Phase ii evaluation of ftorafur in previ

Phase ii evaluation of ftorafur in previously untreated colorectal cancer: A southwest oncology group study

✍ Thomas Buroker; Fernando Padilla; Carl Groppe; Gerald Guy; Joseph Quagliana; Jos 📂 Article 📅 1979 🏛 John Wiley and Sons 🌐 English ⚖ 341 KB 👁 2 views

Phase II evaluation of mitoxantrone in a

Phase II evaluation of mitoxantrone in advanced pancreatic carcinoma: A Southwest Oncology Group study

✍ Sarah A. Taylor; Thomas Fleming; Daniel D. Hoff; Joseph D. McCracken; Ronald M. 📂 Article 📅 1990 🏛 Springer US 🌐 English ⚖ 242 KB

Patient with advanced adenocarcinoma of the pancreas and no prior chemotherapy were treated on a Phase II trial of mitoxantrone. Doses were adjusted for hepatic dysfunction as defined by bilirubin. Twenty-four patients with a bilirubin less than or equal to 1.5 mg% received mitoxantrone 12 mg/m2 i.v

Bisantrene hydrochloride in gastric aden

Bisantrene hydrochloride in gastric adenocarcinoma: A southwest oncology group study

✍ Panettiere, Frank J. ;Jones, Stephen E. ;Oishi, Noboru ;Eyre, Harmon J. ;O'Bryan 📂 Article 📅 1986 🏛 John Wiley and Sons 🌐 English ⚖ 257 KB

Because "the standard" chemotherapy for advanced gastric adenocarcinoma, the FAM combination of 5-fluorouracil, adriamycin, and mitomycin, is only minimally effective, there is a clear need for other choices. Therefore, the Southwest Oncology Group tested the new adriamycin analog, bisantrene, hopin